These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 29205284)

  • 21. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
    Jarnagin K; Chanda S; Coronado D; Ciaravino V; Zane LT; Guttman-Yassky E; Lebwohl MG
    J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
    Bissonnette R; Pavel AB; Diaz A; Werth JL; Zang C; Vranic I; Purohit VS; Zielinski MA; Vlahos B; Estrada YD; Saint-Cyr Proulx E; Ports WC; Guttman-Yassky E
    J Allergy Clin Immunol; 2019 Nov; 144(5):1274-1289. PubMed ID: 31419544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
    Yang H; Wang J; Zhang X; Zhang Y; Qin ZL; Wang H; Luo XY
    JAMA Dermatol; 2019 May; 155(5):585-593. PubMed ID: 30916723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis.
    Ma L; Tao X; Liu S; Cheng H; Fang R; Zhao Y; Cha A; Encinas GA; Zhou Y; Deng Y; Zhang J
    Dermatol Ther (Heidelb); 2024 May; 14(5):1229-1243. PubMed ID: 38748345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
    Silverberg JI; Kirsner RS; Margolis DJ; Tharp M; Myers DE; Annis K; Graham D; Zang C; Vlahos BL; Sanders P
    J Am Acad Dermatol; 2024 May; 90(5):945-952. PubMed ID: 38340127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
    Yosipovitch G; Gold LF; Lebwohl MG; Silverberg JI; Tallman AM; Zane LT
    Acta Derm Venereol; 2018 Apr; 98(5):484-489. PubMed ID: 29363715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
    Eichenfield LF; Call RS; Forsha DW; Fowler J; Hebert AA; Spellman M; Stein Gold LF; Van Syoc M; Zane LT; Tschen E
    J Am Acad Dermatol; 2017 Oct; 77(4):641-649.e5. PubMed ID: 28823881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis.
    Thom H; Cheng V; Keeney E; Neary MP; Eccleston A; Zang C; Cappelleri JC; Cha A; Thyssen JP
    Dermatol Ther (Heidelb); 2022 Jan; 12(1):185-194. PubMed ID: 34877623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis.
    Geng B; Hebert AA; Takiya L; Miller L; Werth JL; Zang C; Sanders P; Lebwohl MG
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1667-1678. PubMed ID: 34379285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis.
    Ono R; Yagi M; Shoji A; Fujita K; Yoshida M; Ports WC; Purohit VS
    J Dermatol; 2020 Jan; 47(1):25-32. PubMed ID: 31657024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis.
    Woo TE; Kuzel P
    Skin Therapy Lett; 2019 Mar; 24(2):4-6. PubMed ID: 30970204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis.
    Saeki H; Baba N; Oshiden K; Abe Y; Tsubouchi H
    J Dermatol; 2020 Jan; 47(1):17-24. PubMed ID: 31713267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
    Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS
    Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
    Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
    Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole.
    Ständer S; Yosipovitch G; Bushmakin AG; Cappelleri JC; Luger T; Tom WL; Ports WC; Zielinski MA; Tallman AM; Tan H; Gerber RA
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1742-1746. PubMed ID: 31132182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
    Cheape AC; Murrell DF
    Expert Rev Clin Immunol; 2017 May; 13(5):415-423. PubMed ID: 28290219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.
    Purohit V; Riley S; Tan H; Ports WC
    J Clin Pharmacol; 2020 Oct; 60(10):1344-1354. PubMed ID: 32433779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translating the Investigator's Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis.
    Thyssen JP; Zang C; Neary MP; Bushmakin AG; Cappelleri JC; Cha A; Russo C; Luger TA
    Dermatol Ther (Heidelb); 2021 Jun; 11(3):845-853. PubMed ID: 33728583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.